The increasing overlap between metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes (T2D) demands earlier detection and more integrated care strategies, according to recent findings highlighted by the American Journal of Managed Care® (AJMC®).
MASLD, a condition formerly known as nonalcoholic steatohepatitis (NASH), is now understood to be driven by metabolic dysfunction, not simply the absence of alcohol consumption. This reclassification underscores the strong link between metabolic disorders like obesity and diabetes and the progression of liver disease. The AJMC® reports emphasize that the prevalence of both MASLD and T2D is rising globally, creating a significant public health challenge.
Current diagnostic approaches often identify MASLD at a late stage, when significant liver damage has already occurred. Experts are advocating for proactive screening in individuals with risk factors for metabolic syndrome, including those with T2D. Integrated care models, where liver specialists and diabetes care teams collaborate, are seen as crucial for optimizing patient outcomes. These models would facilitate earlier intervention and a more holistic approach to managing both conditions simultaneously.
Research indicates that individuals with both MASLD and T2D face a heightened risk of adverse health outcomes, including cirrhosis, liver failure, cardiovascular disease, and kidney disease. The interplay between these conditions creates a complex clinical picture, requiring tailored treatment plans.
Emerging therapies are also showing promise in addressing MASLD. A recent study, also published in the AJMC®, detailed the positive impact of efruxifermin in combination with a GLP-1 receptor agonist on outcomes in patients with MASH (Metabolic dysfunction-associated steatohepatitis). This combination therapy demonstrated improved histological features of liver disease.
Alongside pharmacological interventions, lifestyle modifications remain a cornerstone of MASLD management. Weight loss through diet and exercise, along with improved glycemic control in patients with T2D, are essential for slowing disease progression. Bariatric surgery has also been shown to reduce metabolic comorbidities in patients with obesity, offering another potential avenue for intervention, according to AJMC® reporting.
Despite growing awareness and research efforts, significant gaps remain in the understanding and management of MASLD and its relationship with T2D. Further research is needed to identify optimal screening strategies, refine diagnostic criteria, and develop more effective therapies. The AJMC® continues to publish research on these topics.
